Design Therapeutics Inc DSGN Q1 2026 Earnings NarrowerThanExpected Loss Highlights Progress in Gene Therapy Pipeline LOW Q1 2026 Earnings EPS Beats Estimates Revenue Data Not Disclosed CNTY Q1 2026 Earnings EPS Beats Estimates Despite Continued Loss HSIC Q1 2026 Earnings Strong EPS Beat Amid Solid Operational Performance BCRX Q1 2026 Earnings Significant EPS Miss Despite Positive Stock Reaction CATO Q4 2025 Earnings Wider Loss Reported as Shares Slide